Skip to main content
SBFM logo

Sunshine Biopharma, Inc.

SBFMNASDAQHealthcareDrug Manufacturers - Specialty & Generic

$0.22Today:- (-)1Y −89.00%

As of Oct 16, 2026 close

Market cap
$314.02K
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.21$23.20
Volume (live)
-
Avg. volume (3M)
10.45M

Sunshine Biopharma (SBFM) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Sunshine Biopharma used $5.33M of cash in operating activities and spent $836.31K on capital expenditures. That left free cash flow of −$6.17M.

Sunshine Biopharma Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Sunshine Biopharma, Inc. (SBFM) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2023FY 2022FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Mar 2024Dec 2023Mar 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-5.98-5.13-4.51-4.51-26.74-26.74-12.44-2.78-1.66-2.16-1.04
Depreciation & Amortization0.330.220.150.150.030.030.010.010.010.050.01
Change in Working Capital-1.45-5.38-4.42-4.423.153.15-0.11-0.04-0.030.05-0.02
Change in Accounts Receivable-0.12-2.34-0.59-0.59-0.52-0.52-0.010.000.00-0.020.00
Change in Inventory-1.64-6.01-2.37-2.370.040.04-0.08-0.01-0.020.000.00
Change in Accounts Payable-0.193.98-1.36-1.363.363.60-0.02-0.04-0.020.06-0.01
Change in Other Working Capital0.50-1.02-0.09-0.020.28-0.010.000.000.000.01-0.01
Other Operating Activities1.76-2.240.00-18.32-0.0110.702.161.181.540.51
Net Cash from Operating Activities-5.33-12.53-8.78-8.78-5.25-5.25-1.83-0.66-0.50-0.51-0.54
Investing Activities
Capital Expenditures-0.84-2.32-0.79-0.08-0.30-0.300.000.000.00-0.020.00
Acquisitions0.000.000.00--14.35-14.350.000.000.000.00-0.08
Sales/Maturities of Investments0.000.000.00-0.710.00-0.110.000.000.000.000.00
Other Investing Activities0.00-0.32-0.570.13-0.080.030.000.00-0.010.000.00
Net Cash from Investing Activities-0.84-2.32-0.66-0.66-14.62-14.620.000.00-0.02-0.01-0.08
Financing Activities
Debt Repayment0.000.35-0.13-0.13-1.93-1.902.901.610.420.470.57
Common Stock Issued1.8312.084.094.0943.5630.370.000.000.000.000.06
Common Stock Repurchased0.00-3.14-0.54-0.54-0.10-0.100.000.000.000.000.00
Other Financing Activities0.000.000.00-0.13-2.06-2.060.000.000.030.060.04
Net Cash from Financing Activities4.759.293.433.4339.4739.472.901.610.440.530.67
Summary
Effect of Forex Changes on Cash0.86-1.040.470.470.180.18-0.020.00-0.010.010.01
Net Change in Cash-1.42-6.61-5.53-5.5319.7819.601.060.95-0.070.010.05
Cash at Beginning of Period9.6916.2921.8321.832.052.050.990.040.120.110.06
Cash at End of Period9.129.6916.2916.2921.8321.832.050.990.040.120.11
Free Cash Flow-6.17-14.85-9.56-8.86-5.55-5.55-1.83-0.66-0.50-0.53-0.55
Supplemental Disclosures
Interest Paid-0.01---0.050.040.02---
Income Taxes Paid-0.58---------

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Sunshine Biopharma Cash Flow

What is Sunshine Biopharma's free cash flow?

Sunshine Biopharma had negative free cash flow of $6.17M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$5.33M minus $836.31K of capital expenditures.

How much does Sunshine Biopharma spend on capital expenditures?

Sunshine Biopharma spent $836.31K on capital expenditures in fiscal 2025, compared with $2.32M a year earlier.

Does Sunshine Biopharma pay dividends or buy back shares?

Sunshine Biopharma's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition